🅇
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient.
Status
Recruiting
Phase
PHASE2
NCT ID
NCT06496620
Trial Summary
A Randomized, Double-blind, Placebo-controlled, Multiple Dose-Ranging Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Solrikitug in Participants with Chronic Obstructive Pulmonary Disease (COPD).
Sponsor: Uniquity One (UNI)
Participants: ALL
Start: 2024-08-14
Completion: 2026-06-30
Min Age: 40 Years
Max Age: 75 Years
Eligibility Criteria
Inclusion Criteria: * At least 40 years of age and no older than 75 years. * Documented diagnosis of COPD for at least 12 months prior to Screening, defined by the GOLD Guidelines (2023), and elevated blood eosinophils at screening. * At Screening FEV1/FVC ratio must be
Data from ClinicalTrials.gov. Always verify on the primary source before clinical use.
More in Respiratory / COPD / Asthma
NICE
Chronic Obstructive Pulmonary Disease in Over 16s: Diagnosis and Management (NICE NG115)
25 Mar 2026
NICE
Asthma: Diagnosis, Monitoring and Chronic Asthma Management (NICE NG80/BTS)
25 Mar 2026
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III…
25 Mar 2026